Immune checkpoint inhibitors in infectious disease
Hannah A. D. King,Sharon R. Lewin
DOI: https://doi.org/10.1111/imr.13388
2024-09-11
Immunological Reviews
Abstract:Summary Following success in cancer immunotherapy, immune checkpoint blockade is emerging as an exciting potential treatment for some infectious diseases, specifically two chronic viral infections, HIV and hepatitis B. Here, we will discuss the function of immune checkpoints, their role in infectious disease pathology, and the ability of immune checkpoint blockade to reinvigorate the immune response. We focus on blockade of programmed cell death 1 (PD‐1) to induce durable immune‐mediated control of HIV, given that anti‐PD‐1 can restore function to exhausted HIV‐specific T cells and also reverse HIV latency, a long‐lived form of viral infection. We highlight several key studies and future directions of research in relation to anti‐PD‐1 and HIV persistence from our group, including the impact of immune checkpoint blockade on the establishment (AIDS, 2018, 32, 1491), maintenance (PLoS Pathog, 2016, 12, e1005761; J Infect Dis, 2017, 215, 911; Cell Rep Med, 2022, 3, 100766) and reversal of HIV latency (Nat Commun, 2019, 10, 814; J Immunol, 2020, 204, 1242), enhancement of HIV‐specific T cell function (J Immunol, 2022, 208, 54; iScience, 2023, 26, 108165), and investigating the effects of anti‐PD‐1 and anti‐CTLA‐4 in vivo in people with HIV on ART with cancer (Sci Transl Med, 2022, 14, eabl3836; AIDS, 2021, 35, 1631; Clin Infect Dis, 2021, 73, e1973). Our future work will focus on the impact of anti‐PD‐1 in vivo in people with HIV on ART without cancer and potential combinations of anti‐PD‐1 with other interventions, including therapeutic vaccines or antibodies and less toxic immune checkpoint blockers.
immunology